(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 June 2013 (06.06.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/080147 A3

(51) **International Patent Classification**:
A61K 38/00 (2006.01) *C07K 14/435* (2006.01)
C07K 14/705 (2006.01) *C07K 19/00* (2006.01)
C07K 14/52 (2006.01) *C12N 9/24* (2006.01)

(21) **International Application Number**:
PCT/IB2012/056806

(22) **International Filing Date**:
28 November 2012 (28.11.2012)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
P.397167 28 November 2011 (28.11.2011) PL

(71) **Applicant**: **ADAMED SP. Z O.O.** [PL/PL]; Pieńków 149, PL-05-152 Czosnów k/Warszawy (PL).

(72) **Inventors**: **PIECZYKOLAN, Jerzy Szczepan**; Gorajec - Zastawie 47, PL-22-463 Radecznica (PL). **PAWLAK, Sebastian**; ul Majakowskiego 3/2, PL-01-420 Warszawa (PL). **SZYMANIK, Michal**; ul. Elektryków 4 m.7, PL-05-270 Marki (PL). **PIECZYKOLAN, Anna Maria**; ul. Skarbka z Gór 124A/2, PL-03-287 Warszawa (PL). **ŻEREK, Bartlomiej Maciej**; ul. Południowa 45/4, PL-97-200 Dąbrowa (PL). **RÓZGA, Piotr**; ul. Bolesława Prusa 6/18, PL-96-100 Skierniewice (PL). **JAWORSKI, Albert Robert**; ul. Węgrowska 3/116, PL-03-507 Warszawa (PL). **TESKA-KAMINSKA, Malgorzata Izabela**; Korytowska 19G Święcice, PL-05-860 Płochocin (PL).

(74) **Agent**: **SITKOWSKA, Jadwiga**; Al. Komisji Edukacji Narodowej 83/106, PL-02-777 Warszawa (PL).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) **Date of publication of the international search report**:
13 February 2014

WO 2013/080147 A3

(54) **Title**: ANTICANCER FUSION PROTEIN

(57) **Abstract**: A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity, preferably 85% identity and ending with the amino acid hTRAIL281; and domain (b) which is a sequence of an effector peptide inhibiting protein synthesis, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases.